NurExone’s Intellectual Property Portfolio Expands
February 20 2024 - 3:05PM
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or
“NurExone”), a pioneering biopharmaceutical company, proudly
underscores its expanding Intellectual Property (IP) portfolio,
which will serve as the foundation for its strategic goal of
licensing the innovative ExoTherapy platform to interested biotech
companies.
NurExone’s Intellectual property portfolio
describes the ExoTherapy platform’s comprehensive technology and
processes for the production of nanodrugs including large scale
production of exosomes, loading of active molecules and the
composition of the exosomes themselves. The loading technology was
presented to the public in the press release of February 12, 2024.
Today the Company is highlighting its innovative bioreactor and
biological processes for:
- High yield repeatable production of exosomes
- Production of natural and potent exosomes (not synthetically
engineered)
Dr. Lior Shaltiel, CEO of NurExone, emphasized,
“Exosomes are known for their innate regenerative abilities and are
becoming increasingly important in both the healthcare sectors and
even aesthetics. With our proprietary production and loading
advantages, NurExone is advancing development of nanodrugs that use
exosomes as a Bio-delivery system, beginning with ExoPTEN. In
addition, our ExoTherapy platform is expected to have broad appeal
to the pharma industry for a wide range of potential collaborations
which are expected to yield cutting edge nanodrugs and a stable
revenue stream for the company.”
Scientific results and initiatives have
demonstrated efficiency of the Company’s large-scale production
process, its effectiveness of the Company’s proprietary
small-interfering RNA (“siRNA”) sequences as therapeutic agent and
the technology for loading veracity of therapeutic molecules into
exosomes. Aspects of the company’s platform which relate to
Extracellular Vesicles (EVs) production are described in a growing
intellectual property portfolio with two PCT applications currently
in National Phases.
The first application disclosed unique
three-dimensional (3D) porous scaffold that induce physiological
changes in the cells, which result in enhanced secretion of EVs and
in improved biological effect of the Evs on mammalian cells. This
international patent application is currently pending in US, EU,
AU, SG and IL. The second international patent application further
elaborate the EV composition produced by the 3D system as well as
the treatment of diseases and disorders associated with such
composition. This international patent application is currently
pending in US, EU, AU, IL and IN.
Both applications, once granted, will provide
NurExone patent protection over unique and effective platform that
will maximize EVs quality. These EVs will be used for the
development and manufacturing of diverse medicament for various
diseases as will be developed by the NurExone team. Such
developments are the basis of additional patent families.
NurExone has an exclusive license from the
Technion (Israel Institute of Technology) over novel patent family
that claim a system and method for producing Extracellular Vesicles
(EVs) from stem cells for other types of indications as well.
Professor Shulamit Levenberg, Director of the Technion Center for
3D Bioprinting and Chief Scientific Advisor at NurExone, and her
team lab is behind this technology. This patent family bundled
together two international patent applications.
About NurExone Biologic Inc.NurExone Biologic
Inc. is a TSXV listed pharmaceutical company that is developing a
platform for biologically-guided exosome-based therapies to be
delivered, non-invasively, to patients who have suffered Central
Nervous System injuries. The company’s first product, ExoPTEN for
acute spinal cord injury, was proven to recover motor function in
75% of laboratory rats when administered intranasally. ExoPTEN has
received Orphan Drug Designation from the FDA with first-in-human
expected in 2025. The NurExone platform technology is expected to
offer novel solutions to drug companies interested in noninvasive
targeted drug delivery for other indications.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS This press release
contains certain forward-looking statements, including statements
about the Company's future plans and intellectual property, the
scientific and development and commercial activities to be carried
out by the company, the efficient loading of exosomes, future
potential manufacturing, clinical, licensing and marketing
activities and the treatment of certain conditions. Wherever
possible, words such as "may", "will", "should", "could", "expect",
"plan", "intend", "anticipate", "believe", "estimate", "predict" or
"potential" or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. These statements reflect management's
current beliefs and are based on information currently available to
management as at the date hereof. Forward-looking statements
involve significant risk, uncertainties and assumptions. Many
factors could cause actual results, performance or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Certain assumptions include the ability
of the Company to commercialize its intellectual property
internally and through licensing and that the Company has the
appropriate team in order to realize commercialization. Risks and
uncertainties include, but are not limited to, risks related to the
Company's early stage of development, lack of revenues to date,
government regulation, market acceptance for its products, rapid
technological change, dependence on key personnel, protection of
the Company's intellectual property and dependence on the Company's
strategic partners. These factors should be considered carefully
and readers should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be
reasonable assumptions, the Company cannot assure readers that
actual results will be consistent with these forward-looking
statements. These forward-looking statements are made as of the
date of this press release, and the Company assumes no obligation
to update or revise them to reflect new events or circumstances,
except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
Historical Stock Chart
From Aug 2024 to Sep 2024
NurExone Biologic (TG:J90)
Historical Stock Chart
From Sep 2023 to Sep 2024